ClinConnect ClinConnect Logo
Search / Trial NCT00002827

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Launched by CHILDREN'S ONCOLOGY GROUP · May 25, 2004

Trial Information

Current as of July 30, 2025

Completed

Keywords

Stage Ii Childhood Hodgkin Lymphoma Stage I Childhood Hodgkin Lymphoma Stage Iii Childhood Hodgkin Lymphoma Cardiac Toxicity

ClinConnect Summary

OBJECTIVES: I. Modify chemotherapy courses based on initial response to therapy in children with newly diagnosed stage IA/IIA/IIIA1 Hodgkin's disease. II. Examine the activity of variable courses of doxorubicin, bleomycin, vincristine, and etoposide (DBVE) followed by low-dose involved-field irradiation in these patients. III. Monitor the safety and feasibility of the response-dependent approach and the morbidity and immediate and long-term toxic effects associated with this regimen. IV. Assess whether limited therapy is adequate for patients with an early response. V. Evaluate whether the ...

Gender

ALL

Eligibility criteria

  • DISEASE CHARACTERISTICS: Histologically proven Hodgkin's disease No more than 5 weeks since diagnostic biopsy No B symptoms Clinical/pathologic stages (all histologies) as follows: Stage IA/IIA with mediastinal mass less than one third of chest diameter Stage IIIA limited to spleen or splenic, celiac, or portal nodes and lesions no larger than 6 cm Surgical staging required if: Clinical and imaging findings equivocal Tanner stage IV/V for whom radiotherapy is planned Concurrent registration on protocols POG-8828 (late effects study) and POG- 8829 (epidemiology study) required
  • PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Hematopoietic: No hematopoietic disease Hepatic: No liver disease Renal: No renal disease Other: No severe organ or system damage or failure No pregnant or nursing women
  • PRIOR CONCURRENT THERAPY: No prior therapy

About Children's Oncology Group

The Children's Oncology Group (COG) is a leading national organization dedicated to improving the care and outcomes of children with cancer through collaborative research and clinical trials. Comprising a network of pediatric oncology experts, COG focuses on developing innovative treatment protocols, advancing scientific knowledge, and enhancing the quality of life for young patients. By fostering interdisciplinary collaboration and utilizing a comprehensive approach to childhood cancer, COG aims to translate research findings into effective therapies, ultimately striving for a cure for all children diagnosed with cancer.

Locations

Philadelphia, Pennsylvania, United States

Seattle, Washington, United States

New York, New York, United States

Houston, Texas, United States

Ann Arbor, Michigan, United States

New York, New York, United States

Rochester, Minnesota, United States

Los Angeles, California, United States

Chicago, Illinois, United States

Indianapolis, Indiana, United States

Iowa City, Iowa, United States

Minneapolis, Minnesota, United States

Chapel Hill, North Carolina, United States

Cleveland, Ohio, United States

San Francisco, California, United States

Kalamazoo, Michigan, United States

Nashville, Tennessee, United States

Fargo, North Dakota, United States

Travis Air Force Base, California, United States

Madison, Wisconsin, United States

New York, New York, United States

Salt Lake City, Utah, United States

Fargo, North Dakota, United States

New Brunswick, New Jersey, United States

Omaha, Nebraska, United States

Long Beach, California, United States

Los Angeles, California, United States

Orange, California, United States

Denver, Colorado, United States

Washington, District Of Columbia, United States

Cincinnati, Ohio, United States

Columbus, Ohio, United States

Portland, Oregon, United States

Pittsburgh, Pennsylvania, United States

Seattle, Washington, United States

Perth, Western Australia, Australia

Vancouver, British Columbia, Canada

Halifax, Nova Scotia, Canada

Kansas City, Missouri, United States

Patients applied

0 patients applied

Trial Officials

Cameron K. Tebbi, MD

Study Chair

St. Joseph's Children's Hospital of Tampa

Michael A. Weiner, MD

Study Chair

Herbert Irving Comprehensive Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials